Role of sorafenib on inhibition of growth of human hepatocellular carcinoma cells in vitro
Author:
Affiliation:

Clc Number:

R735.7

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective: To investigate the influence of sorafenib on growth and expressions of tumor-related genes in human hepatocellular carcinoma (HCC) cells in vitro. Methods: Human HCC cells (Hep3B2.1-7) were exposed to different concentrations (0, 5, 10, and 20 μmol/L) of sorafenib for 24 h, and then, the cell proliferation was analyzed by CCK-8 assay, and the mRNA and protein expressions of p53, PTEN and TGF-β1 in the HCC cells were determined by real-time PCR and Western blot, respectively. Results: Compared with the group of cells with 0 μmol/L sorafenib treatment (control group), in the other groups of cells with sorafenib treatment, the cell proliferation rates were all significantly decreased (all P<0.05); the mRNA and protein expressions of p53 and PTEN were significantly increased, while the mRNA and protein expressions of TGF-β1 were significantly decreased (all P<0.05). All these effects of sorafenib showed a certain concentration-dependent manner. Conclusion: Sorafenib can inhibit the growth of human HCC cells in vitro, and the mechanism may be attributed to its regulating the expressions of tumor-related genes.

    Reference
    Related
    Cited by
Get Citation

LI Keyue, SHI Chengxian, TANG Keli. Role of sorafenib on inhibition of growth of human hepatocellular carcinoma cells in vitro[J]. Chin J Gen Surg,2015,24(7):958-962.
DOI:10.3978/j. issn.1005-6947.2015.07.008

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:May 20,2015
  • Revised:June 09,2015
  • Adopted:
  • Online: July 15,2015
  • Published: